Webcast of Conference Call
Anadys will host a conference call at 5:00 p.m. EDT today to discuss its second quarter financial results and highlights and to provide an update on its development programs. A live webcast of the call will be available online at http://www.anadyspharma.com. A telephone replay will also be available approximately one hour after completion of the call. To access the telephone replay, dial 888-286-8010 (domestic) or 617-801-6888 (international), passcode 79911148. The webcast and telephone replay will be available through August 13, 2008.
Anadys Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of chronic hepatitis C, the Company is developing ANA598, a non-nucleoside polymerase inhibitor, and ANA773, an oral TLR7 agonist prodrug. The Company is also developing ANA773 for the treatment of cancer.
Safe Harbor Statement
Statements in this press release that are not strictly historical in
nature constitute "forward-looking statements." Such statements include,
but are not limited to, references to the expected timing and planned
development activities for ANA598 and ANA773, including the occurrence,
timing and pace of future clinical trials, and the anticipated future
clinical benefits of ANA598 and ANA773. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors, which may
cause Anadys' actual results to be materially different from historical
results or from any results expressed or implied by such forward-looking
statements. For example, the results of preclinical studies may not be
predictive of future results, and Anadys
|SOURCE Anadys Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved